This study found agreement with other findings in the assertive use of markers, primarily CD32, CD34, and FLI-1, in standard angiosarcoma diagnosis; however, it emphasizes the importance of molecular research for genes that express differently among patients, which could cause variations in disease progression and, as a result, affect treatment decisions. Here, FLI1 is linked to angiosarcoma.